Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >
Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis
This item is licensed under:Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Title: | Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis |
Authors: | Kuwatani, Masaki Browse this author →KAKEN DB | Kawakami, Hiroshi Browse this author →KAKEN DB | Kubota, Yoshimasa Browse this author | Kawakubo, Kazumichi Browse this author | Ito, Yoichi M. Browse this author →KAKEN DB | Togo, Shinji Browse this author | Ikeda, Takaaki Browse this author | Kusama, Ken Browse this author | Kobayashi, Yuka Browse this author | Murata, Teizo Browse this author | Sakamoto, Naoya Browse this author →KAKEN DB |
Keywords: | CA19-9 | CEA | Fucosylated haptoglobin | Pancreatic cancer | Lectin |
Issue Date: | Jun-2019 |
Publisher: | Elsevier |
Journal Title: | Pancreatology |
Volume: | 19 |
Issue: | 4 |
Start Page: | 569 |
End Page: | 577 |
Publisher DOI: | 10.1016/j.pan.2019.04.007 |
PMID: | 31031206 |
Abstract: | Background: Fucosylated haptoglobin detected by Pholiota squarrosa lectin (PhoSL) that had specificity for fucose alpha 1-6 was reported as an effective biomarker for several gastrointestinal diseases. The aim of this study was to verify Fucosylated haptoglobin detected by Pholiota squarrosa lectin (PhoSL-HP) as a pancreatic cancer (PC) marker using a new method of PhoSL-ELISA. Methods: PhoSL-HP in sera from 98 PC patients and 158 non-PC samples including 32 intraductal papillary mucinous neoplasm (IPMN) patients, 21 chronic pancreatitis (CP) patients and 105 non-pancreatic disease controls (NPDC) were measured. We compared sensitivities, specificities and areas under the curves (AUC) of PhoSL-HP, CA19-9 and CEA as single markers. We also evaluated PhoSL-HP as combination marker by comparing AUC of CA19-9 combined with PhoSL-HP or CEA. Results: The sensitivities of PhoSL-HP, CA19-9 and CEA for PC were 58%, 76% and 42%, respectively. Although the specificity of PhoSL-HP for NPDC was inferior to both of CA19-9 and CEA, that for pancreatic diseases was higher than both of CA19-9 and CEA. Combined CA19-9 with PhoSL-HP, the AUC was significantly higher at 0.880 than single use of CA19-9 at 0.825 in case of distinguishing PC from other pancreatic diseases. In contrast, the AUC of CA19-9 was not elevated significantly when combined with CEA. Conclusion: PhoSL-HP would be a useful marker for PC and have sufficient complementarity for CA19-9. (C) 2019 Published by Elsevier B.V. on behalf of IAP and EPC. |
Rights: | © 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
Type: | article (author version) |
URI: | http://hdl.handle.net/2115/78262 |
Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 桒谷 将城
|